Cost-Effectiveness of Rivaroxaban in the Prevention of Stroke in Non-Valvular Atrial Fibrillation Patients in Italy
2013 Value in health
Capri, S. | Veneziano, M. | Ricciardi, W.G. | D'Ausilio, A. | Pedone, M.P. | Bianchi, C. |
To perform a cost-effectiveness analysis of rivaroxaban (once-daily) in the prevention of stroke and systemic embolism of patients with non-valvular atrial fibrillation (NVAF) and in patients sub-groups from the perspective of the Italian health care system (SSN).